The outlook for those with cystic fibrosis (CF) has never been brighter with ever increasing
life expectancy and the approval of the highly effective CFTR modulators, such as …

The outcome of acute kidney injury (AKI) as a result of aminoglycosides (AGs) use remains
uncertain in patients without prior chronic kidney disease (CKD). Therefore, we explored the …

Aminoglycosides are commonly used for the treatment of Pseudomonas aeruginosa (PsA) in
the setting of acute pulmonary exacerbations (PEx) in pediatric patients with cystic fibrosis …

Background Long-term treatment with inhaled antibiotics is recommended for people with
cystic fibrosis (pwCF) chronically infected with Pseudomonas aeruginosa (PA). However …

The excretion of endogenous and exogenous compounds is a fundamental aspect of renal
function, which, by necessity, exposes the kidney to high concentrations of these substances …

Objectives Colistimethate sodium and tobramycin are important systemic antibiotics for
treatment of cystic fibrosis (CF) pulmonary exacerbations but can induce acute kidney injury …

Objectives To evaluate the incidence of aminoglycoside-related nephrotoxicity and ascertain
drug causality and its risk factors. Methods This prospective study was conducted from …

This chapter provides a review of serious adverse effects associated with miscellaneous
antibiotics, primarily derived from patient cases. Meta analyses and cohort studies were …

Neutrophils in cystic fibrosis (CF) lungs are reprogrammed into a granule-releasing
phenotype associated with proteolytic airway damage. Triggers of this process are unknown; …

Background Once daily intravenous (iv) treatment with tobramycin for Pseudomonas
aeruginosa infection in patients with cystic fibrosis (pwCF) is frequently monitored by …